![85: Pedro Correa de Sampaio: Biotech e Empreendedorismo Científico em Oncologia [PT]](https://is1-ssl.mzstatic.com/image/thumb/Podcasts126/v4/91/38/d9/9138d920-1a8b-c96e-4f46-8e65dbadd6ed/mza_9737997980080240958.jpg/250x250bb.jpg)
Afleveringen
-
Neste episódio do Podcast CRUZAMENTO, André Correia e Daniel Guedelha conversam com Cristina Campos que partilhou as suas experiências sobre o que significa ser uma líder numa grande multinacional em Portugal, liderando centenas de pessoas e enfrentando mudanças de carreira significativas. Discutimos também a importância de viver com propósito e o conceito de uma carreira em portfólio. Além disso, a Cristina ofereceu as suas perspectivas sobre o ecossistema de saúde e os líderes do futuro.
Cristina Campos é sócia e gestora de um grupo familiar de farmácias. Co-fundadora e presidente da Assembleia Geral de uma associação privada sem fins lucrativos – a TOP Health – que tem como objeto impulsionar, promover, reconhecer e galvanizar o talento em saúde, estimulando uma cultura de excelência e de colaboração entre os diferentes interlocutores do sector, com o propósito de criação de mais valor para os profissionais de saúde e para os resultados em saúde da população. Membro da Direção da UNA (United Nations Association) Portugal e do Supervisory Board do Alumni da Nova SBE e de alguns Conselhos Consultivos. Investidora e mentora. Anteriormente, esteve 18 anos (2004–2022) na Novartis, onde desempenhou diversas funções em Portugal entre as quais a de Presidente do Grupo Novartis durante 9 anos e Diretora Geral da Novartis Farma durante 8 anos (desde 2012). Desde 2021 foi membro do Board da Novartis Global Health e do Novartis ESG Council. Nos primeiros anos da sua carreira trabalhou na Merck Sharp & Dohme e na Procter & Gamble. Nas três multinacionais por onde passou desempenhou funções diversas de gestão e liderança fundamentalmente nas áreas comerciais e de marketing. Foi Vice Presidente da Apifarma - Associação Portuguesa da Indústria Farmacêutica - entre 2015 e 2021 e Presidente do Board do Alumni Club do The Lisbon MBA (Católica|Nova|MIT) entre 2018 e 2021. É licenciada em Ciências Farmacêuticas pela Faculdade de Farmácia da Universidade de Lisboa e fez um MBA na Católica|Nova School of Business. É mãe do André (22), Mateus (20) e Joana (18).
Contacts | Contactos:
CruzamentoPodcast.com [email protected] LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento Instagram: @cruzamentopodcast YouTube: Podcast CruzamentoEpisódio editado por João Cunha Studios
-
Neste episódio do Podcast CRUZAMENTO, André Correia e Daniel Guedelha conversam com António Lopes sobre como a Inteligência Artificial (IA) e Machine Learning (ML) estão a transformar a saúde. Por exemplo, como a IA simula a inteligência humana em máquinas, enquanto ML ensina essas máquinas a aprender com dados. Exploram aplicações práticas, como a detecção precoce de doenças, tais como, modelos do MIT e da Harvard Medical School conseguem prever cancro da mama e pâncreas anos antes do diagnóstico tradicional. Falam também sobre o uso da IA na personalização de tratamentos e na aceleração do desenvolvimento de medicamentos. Por fim, abordam os desafios éticos e técnicos dos países e organizações, como a transparência dos algoritmos e a importância do pensamento crítico na análise dos resultados.
António Lopes é Doutorado em Ciências e Tecnologias da Informação - ramo de Inteligência Artificial (2011, Iscte) e é Investigador de Inteligência Artificial Aplicada no pólo de investigação do Iscte do Instituto de Telecomunicações. Lecionou diversas cadeiras de programação e sistemas de informação no Departamento de Ciências e Tecnologias de Informação do Iscte ocasionalmente desde 2001 e com mais regularidade entre 2008 e 2013. É atualmente o coordenador do Gabinete de Desenvolvimento de Sistemas de Informação do ISCTE.
Other relevant references | Outras referências relevantes:
Apresentações referidas na conversa estão disponíveis no YouTube @cruzamentopodcast Podcast Cruzamento # 53: António Lopes e Bruno Amaral: Inteligência artificial e robôs na saúde Podcast Cruzamento # 78: Alan Triggs: Leadership, Longevity and the AI Revolution António Lopes / ISCTE: IA na Medicina: Desafios e Oportunidades (YouTube)Contacts | Contactos:
CruzamentoPodcast.com [email protected] LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento Instagram: @cruzamentopodcast YouTube: Podcast CruzamentoEpisódio editado por João Cunha Studios
-
Zijn er afleveringen die ontbreken?
-
Neste episódio do Podcast CRUZAMENTO, André Correia e Daniel Guedelha conversam com Rui Soares e Filipe Freitas Pinto sobre o ecossistema da tecnologia de saúde e a transformação digital. Filipe destaca a missão da Knokcare na transformação digital da medicina e a importância de personalizar soluções digitais para atender às necessidades dos pacientes. Rui fala sobre a AgentifAI e a implementação de assistentes digitais inteligentes que trazem empatia e melhoram a interação com pacientes. Exemplos concretos incluem a utilização de IA para automatizar processos e melhorar a experiência do paciente, evidenciando que, embora o foco deva ser no futuro, é essencial resolver os desafios atuais.
Rui Soares 56 anos, casado há 25 anos, com 2 filhos (já adultos 😀) , 1 cão, economista de formação e com mais de 25 anos de experiência no setor financeiro, onde desempenhei funções de responsabilidade pela rede comercial, área de marketing, recursos humanos, Banca e Transformação Digital. Desde sempre apaixonado pela área de tecnologia e de como a mesma é um enabler da transformação de negócio das empresas, aceitei o desafio há 1 ano e meio de assumir a responsabilidade Comercial e de Marketing da AgentifAI - empresa portuguesa pioneira e inovadora na área de Conversational AI.
Filipe Freitas Pinto é médico psiquiatra com especialização em medicina farmacêutica e ocupa o cargo de Chief Medical Officer na Knok, empresa líder em telemedicina em Portugal. É um fervoroso impulsionador da adopção de novas tecnologias em cenários reais de saúde, com foco na aplicação prática de Machine Learning e LLMs. Como Google’s Medical AI Ambassador, está na vanguarda das aplicações de AI na medicina. É também docente do Departamento Medicina da Comunidade, Informação e Decisão em Saúde (MEDCIDS) da Faculdade de Medicina da Universidade do Porto.
Other relevant references | Outras referências relevantes:
Podcast Cruzamento # 52: João Magalhães: O futuro, telemedicina mas aumentadaContacts | Contactos:
CruzamentoPodcast.com [email protected] LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento Instagram: @cruzamentopodcast YouTube: Podcast Cruzamento -
Neste episódio do Podcast CRUZAMENTO, André Correia e Daniel Guedelha conversam com Sofia Marta e Luís João sobre o papel transformador da Google Cloud na aceleração da transformação digital em diversas indústrias, com especial foco na saúde, utilizando inteligência artificial para melhorar diagnósticos e tratamentos. Falaram sobre a importância da tecnologia cloud para as startups; e destacaram-se iniciativas de diversidade e inclusão no sector tecnológico. Concluíram com um olhar sobre as tendências emergentes na área da saúde, especialmente a inteligência artificial generativa, e a sua capacidade de trazer empatia e eficiência aos cuidados médicos.
Sofia Marta é Country Manager da Google Cloud em Portugal, sendo responsável pela liderança do negócio e crescimento no mercado. A Sofia tem mais de 20 anos de experiência nas áreas da consultoria e de tecnologia acumulados em diversas empresas. Iniciou a sua carreira na Accenture trabalhando em diversas áreas relacionadas com a modernização do setor público, empresa onde regressou uns anos mais tarde como Vice-Presidente com a responsabilidade de reactivar a prática de Saúde e Administração Pública em Portugal. Desempenhou entretanto funções na Glintt, uma empresa portuguesa da área da saúde, como responsável pelo negócio nacional e internacional de smart processes, bem como na Microsoft Portugal. A Sofia é licenciada em Matemática Científica pela Universidade de Lisboa e conta também com uma Pós-Gradução em eBusiness do ISEG. Tem 46 anos, é casada e tem duas filhas.
Luís João is a senior sales executive with an entrepreneurial spirit and a contagious passion for technology. He is a Status Quo challenger by nature. A Learn-it-all (not a Know-it-all). Simplifier. Trying to inspire everyone through technical leadership. Customer obsessed (listening is good, innovating on customer behalf is great). Luís João is fascinated by people’s potential and growth. Proud mentor and advisor. Results oriented with proven track record and awarded several times. Always a team player (internal and with partners) to compete and win. He speaks on national and international conferences.
Contacts | Contactos:
CruzamentoPodcast.com [email protected] LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento Instagram: @cruzamentopodcast YouTube: Podcast Cruzamento -
In today’s CRUZAMENTO Podcast, André Correia e Daniel Guedelha talk with Hugo Barbosa who take us on a compelling journey from his beginnings in a small northern Portuguese town to a distinguished career spanning multiple countries. Hugo’s insightful discussion delves into the clinical trials cycle, the evolution of drug development, and the transformative power of modern medical science. He talks about the challenges and innovations in pharmaceutical marketing, the critical role of global product teams (GPT), and the strategies for making lifesaving drugs accessible worldwide.
Raised in a small town in northern Portugal in the post-April Revolution fervor for democracy and challenging economic times, Hugo Barbosa 's roots are deeply founded in resilience and hope. With over 25 years in the pharmaceutical industry, including a decade in various international roles, Hugo has cultivated a rich professional journey. His career has taken him across seven cities in three different countries, where he has encountered remarkable individuals, immersed himself in diverse cultures, and broadened his understanding of the world. Hugo believes he can leave the world a little better than he found it. And he tries to do so through the people he interacts with every day, whether at work, at home or at leisure!
Contacts | Contactos:
CruzamentoPodcast.com [email protected] LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento Instagram: @cruzamentopodcast YouTube: Podcast CruzamentoEpisode edited by João Cunha Studios
-
In today’s episode of CRUZAMENTO Podcast, hosts André Correia and Daniel Guedelha sit down with biotech entrepreneur Nuno Prego Ramos to explore the intersection of technology and healthcare. Nuno shares insights into his groundbreaking work at Cellmabs, a biotech company focusing on cancer-specific antigens, and its landmark deal with BioNTech. He also introduces Valvian, his new venture targeting age-related diseases and hard-to-treat tumours using AI-driven immunotherapies. Nuno discusses the importance of developing proprietary AI models for healthcare, the challenges of data privacy, and the necessity of curating high-quality data. The conversation highlights Portugal’s potential as a biotech hub, emphasising the need for talent retention, ecosystem development, and international collaboration to drive innovation in the life sciences sector.
Nuno Prego Ramos is the founder and CEO of Valvian, a Portuguese biotech company launched in January 2024 and announced at the East Coast Grand Investors Conference by Johnson & Johnson Innovation. With a law degree from the University of Lisbon further pursuing a Masters and Ph.D. in Biochemistry and immuno-oncology from Lisbon University, Nuno transitioned from a career in pharmaceuticals to focus on biotechnology. He founded CellmAbs in 2019, developing promising cancer therapies based on humanized monoclonal antibodies. Following the sale of these molecules to BioNTech in January 2024, he established Valvian, aiming to revolutionize cancer and longevity therapies through AI-driven research and to position Portugal as a global biotech leader.
Contacts | Contactos:
CruzamentoPodcast.com [email protected] LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento Instagram: @cruzamentopodcast YouTube: Podcast CruzamentoEpisode edited by João Cunha Studios
-
Neste episódio do Podcast CRUZAMENTO, André Correia e Daniel Guedelha conversam com Pedro Correa de Sampaio, a viver no Reino Unido, que transformou a sua paixão pela investigação em oncologia numa promissora startup biotecnológica, a Neobe Therapeutics. O Pedro partilha como foi a transição do mundo académico para a fundação da Neobe, uma empresa inovadora que utiliza engenharia genética para desenvolver terapias revolucionárias contra o cancro. Explica a analogia do “Cavalo de Tróia” para atacar tumores e discute os desafios de financiamento de startups no Reino Unido, além dos potenciais obstáculos e oportunidades em Portugal. Reflete sobre o talento e a ética de trabalho dos cientistas portugueses no exterior e a necessidade de mudança de mentalidade nas universidades e no sector empresarial português para fomentar o empreendedorismo científico. Uma conversa rica em insights sobre a interseção entre saúde, inovação e transformação digital.
Pedro Correa de Sampaio received his PhD in Oncology from the University of Cambridge, where he first developed his interest in understanding and targeting different components of the tumour microenvironment (TME). He initially focused on the study of angiogenesis – the formation of new blood vessels in cancer, after which he moved to the MD Anderson Cancer Center in Houston, Texas. There, he developed methods to study the spatial interactions between TME components, and observed how they could prevent the effective infiltration of immune cells. That led him to move back to London and found Neobe, an early stage startup aimed at genetically engineering bacteria to disrupt these barriers and enable immunotherapy efficacy in solid tumours.
Other relevant references | Outras referências relevantes:
Neobe Therapeutics (website)Contacts | Contactos:
CruzamentoPodcast.com [email protected] LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento Instagram: @cruzamentopodcast YouTube: Podcast CruzamentoEpisódio editado por João Cunha Studios
-
In today’s CRUZAMENTO Podcast, André Correia e Daniel Guedelha dive into the dynamic world of healthcare’s digital transformation with Francisco Aguiar. From data privacy to precision medicine and wearable health tech, discover how organisations are reshaping patient care and driving innovation. Explore key trends and insights shaping the future of healthcare in this enlightening conversation.
Francisco Aguiar is a passionate project and people manager with over 10 years of experience in the life sciences industry. He leverages his data and analytics background to collaborate with key stakeholders and deliver impactful solutions that benefit both our customers and patients. Fostering career and leadership development within his team is a core value for Francisco. He believes in creating an environment where everyone can thrive and contribute their best work.
Other relevant references | Outras referências relevantes:
BI4ALL: Turning your data into actionable insights (website) Emerald (website)Contacts | Contactos:
CruzamentoPodcast.com [email protected] LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento Instagram: @cruzamentopodcast YouTube: Podcast CruzamentoEpisode edited por João Cunha Studios
-
In this episode of Cruzamento Podcast, hosts André Correia and Daniel Guedelha dive into the intersection of technology and healthcare with special guest Maria Manso, CEO and co-founder of Tucuvi. Maria shares her journey from biomedical engineering to founding Tucuvi, a company dedicated to addressing healthcare capacity challenges using innovative technology. This platform enables autonomous phone consultations, leveraging empathetic conversational AI to engage patients and streamline healthcare delivery. Maria discusses Tucuvi’s impact on patient care, collaboration with healthcare providers and pharmaceutical companies, and expansion into new markets. She highlights the importance of empathy in technology-driven healthcare solutions and invites listeners to connect with Tucuvi on LinkedIn for more information. This engaging conversation offers insights into the future of healthcare innovation and the role of startups in transforming patient-centred care.
María Manso is the Co-Founder and CEO of Tucuvi, a leading company in Conversational Artificial Intelligence in healthcare. Tucuvi works side by side with healthcare systems to help deliver quality care in the most efficient way possible to millions of patients. In 2024, she has been recognized as the Most Promising European Woman Innovator by the European Innovation Council.
Other relevant references | Outras referências relevantes:
TucuviContacts | Contactos:
CruzamentoPodcast.com [email protected] LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento Instagram: @cruzamentopodcast YouTube: Podcast CruzamentoEpisode edited by João Cunha Studios
-
In this episode of the CRUZAMENTO Podcast, hosts André Correia and Daniel Guedelha dive deep into the world of gene sequencing, rare diseases, and the future of healthcare with their guest, Tiago Magalhães. Tiago, a biologist turned bioinformatician, sheds light on the pivotal role of gene sequencing in modern healthcare and its potential to revolutionise patient care. From deciphering the intricacies of raw genomic data to the challenges and opportunities presented by initiatives like the Emirati Genome Program, Tiago provides valuable insights into the intersection of technology and healthcare. The conversation touches upon the high prevalence of rare diseases in the UAE, the impact of genomic data on drug discovery, and the evolving landscape of personalised medicine. Tiago also shares his thoughts on the future of genomics and the vital role of patient advocacy in shaping healthcare outcomes. Throughout the discussion, Tiago’s expertise and passion for the subject shine, making complex topics accessible and engaging for listeners.
Who is Tiago Magalhães?
My name is Tiago Magalhães and I believe in the power of science and knowledge to make the world a better place. I have a Ph.D in genomics and an EMBA in management of research infrastructures. I am currently the Director of Bioinformatics at G42 Healthcare. G42Healthcare is a leading genomics organization, and currently has the largest cohort of long reads in the world. Before my current position, I was VP for Bioinformatics at Genomics Medicine Ireland and before that I was Executive Director at CCMAR, Portugal, a research organization for Marine sciences. I trained as a genomics scientist studying autism, diabetes, bowel cancer, and ancestry analysis. I have a very strong background in biology, namely in animal models, genetic screens, cell biology, microscopy and molecular biology. Words that describe my daily work: very large scale bioinformatics omics work (MGI, Illumina and ONT), analytics, computational biology, drug discovery, human resources supervision, business strategic thinking, and stakeholders management. Another facet of my CV is entrepreneurship, technology transfer and innovation, as I believe that science only makes sense when applied to solve societal challenges. I was the founder and CEO of a personalized medicine start-up, advised several genomics start-ups, and VCs on the genomics space. I am currently an expert for the H2020 European Union programs, and a reviewer for genomics journals. I have worked/studied in Portugal, Germany, US, Canada, East-Timor, Ireland, Brasil and the UAE.
Other relevant references | Outras referências relevantes:
Emirati Genome Program Emirati Genome Program by G42.ai UK BiobankContacts | Contactos:
CruzamentoPodcast.com [email protected] LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento Instagram: @cruzamentopodcast YouTube: Podcast CruzamentoEpisode edited by João Cunha Studios
-
In this engaging episode of the new segment Cruzamento Education, hosts André Correia e Daniel Guedelha delve into the world of value-based healthcare with special guest Filipe Costa. They explore the fundamental concepts of value-based healthcare, discussing its importance in delivering meaningful outcomes for patients while optimising costs. Felipe provides insights into the key topics of patient-reported outcome measurements, technology integration, financial incentives alignment, and the role of data interoperability in supporting value-based healthcare initiatives. The conversation highlights Portugal’s potential to lead the way in implementing value-based healthcare practices and emphasises the importance of transparency, evidence-based decision-making, and collaboration across the healthcare ecosystem.
Filipe Costa’s profile:
Professor in Management & VBHC at Nova SBE Exec. Education Researcher in Nova Healthcare Economics & Management Knowledge Centre- Coordinated by Prof Pedro Pita Barros Executive Coordinator of the Pos Graduation of Healthcare Management NOVA SBE Executive Education Past Director of VBHC in Luz Saúde Group Post Graduated in Harvard Business School- Value Based Healthcare MBA and a master in management Areas of interest and research: value-based health, health management, organizatioal theory, operations management, outcomes, cost analysis, payment models and process improvement. Led several national and international management projects in VBHC Distinguished Merit Award the International Federation of Hospitals 2019 in Patient Cantered Care with the Value project Health care based. Best VBHC Group in Portugal price by Accenture, Jansen, APAH, J. Negocios Several publications and International presentations about VBHCContacts | Contactos:
CruzamentoPodcast.com [email protected] LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento Instagram: @cruzamentopodcast YouTube: Podcast CruzamentoEpisode edited by João Cunha Studios
-
In today’s CRUZAMENTO Podcast, André Correia e Daniel Guedelha talked with Daniel Lewi, co-founder and CEO of the CATS Foundation, about the world of rare disease advocacy. Dan shares his personal journey as a patient advocate and discusses the mission of the CATS Foundation, which focuses on raising awareness and driving research for Tay-Sachs and Sandhoff disease. He highlights the importance of collaboration and transparency in advocating for better treatment options, emphasising the need for data sharing, especially in drug repurposing efforts. Dan also shares insights into engaging with pharmaceutical companies, emphasising the importance of building trust, clear communication, and collaborative strategies. Throughout the conversation, the critical role of patient voices, diverse perspectives, and community involvement in shaping advocacy efforts is emphasised, ensuring that the needs and experiences of individuals impacted by rare diseases are at the forefront of research and development initiatives.
Dan Lewi’s eldest daughter Amelie was diagnosed with Tay-Sachs in 2011 at 15 months of age and upon finding that there was no dedicated advocacy group providing support for families affected by this disease in the UK he set set-up the Cure & Action for Tay-Sachs (CATS) Foundation with his wife Patricia. Since the group was launched, they have been able to grow The CATS Foundation so that it now offers a variety of services to its family members and has been actively involved in the research investigating therapeutic treatments for Tay-Sachs and Sandhoff disease. In addition to this, Dan is the one of the founding members and Chairman of the European Tay-Sachs and Sandhoff Charity Consortium which brings together all the European patient groups leading the fight against the diseases and is part of the team establishing the IGGA, a global organisation bringing together all the advocacy groups for GM1 and GM2. Dan is fully committed to leading the charity towards its goal of finding a treatment so that there is hope for those families affected by Tay-Sachs and Sandhoff in the future
Other relevant references | Outras referências relevantes:
CATS Foundation (website)Contacts | Contactos:
CruzamentoPodcast.com [email protected] LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento Instagram: @cruzamentopodcast YouTube: Podcast CruzamentoEpisode edited by João Cunha Studios
-
Neste episódio do Podcast CRUZAMENTO, André Correia e Daniel Guedelha conversam com Cristina Fraga, CEO da mindout, uma Health Startup focada na saúde mental. Nesta conversa, a Cristina partilha a sua transição do mundo corporativo para o empreendedorismo, discutindo a importância do tema da saúde mental nas empresas e na sociedade. Exploramos o impacto do Burnout, a sua prevalência global e consequências económicas, bem como estratégias para identificar e mitigar esta condição nas organizações. Além disso, abordamos desafios na implementação de programas de prevenção, a importância da liderança na quebra do estigma e como a tecnologia pode ser utilizada para melhorar a saúde mental dos colaboradores, especialmente no contexto do trabalho remoto. Por fim, discutimos a relevância de fornecer suporte e ferramentas para estudantes universitários lidarem com estas questões.
Cristina Fraga é Fundadora e CEO da mindout, uma health/brain-tech startup sediada em Lisboa, que opera na área da saúde mental e está disponível para estudantes universitários, trabalhadores e empresas e profissionais de saúde de todo o mundo. Cristina é Engenheira Informática do IST, trabalhou 8 anos na Deloitte, 2 anos na Deloitte PT e 6 anos na Deloitte US nos escritórios de San Francisco e Manhattan, sempre na área da Tecnologia. Voltou para Portugal em 2013 onde esteve 8 anos na EDP, também ligada ao Digital e Marketing Digital. Em 2020 tirou um Executive MBA no INSEAD e juntou-se à Liberty Insurance como Chief Marketing Officer da Europa. Como sempre teve vontade de criar valor na área da saúde, após a saída de um burnout em 2022, decidiu criar a mindout, utilizando a experiência que viveu nessa mesma jornada, o know-how de business management e liderança com o seu lado tecnológico, para criar uma solução escalável e sustentável para prevenção e reversão de burnouts com uma jornada clara e transparente, com grande foco em Inteligência Artificial.
Other relevant references | Outras referências relevantes:
mindout (website)Contacts | Contactos:
CruzamentoPodcast.com [email protected] LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento Instagram: @cruzamentopodcast YouTube: Podcast CruzamentoEpisódio editado por João Cunha Studios
-
In this episode of Cruzamento Podcast, hosts André Correia and Daniel Guedelha explore the intersections of technology, healthcare, and leadership with Alan Triggs, Chief Digital Officer for Nokia. They delve into the impact of AI on industries, discussing the evolution of AI, its role in job creation and displacement, and its potential impact on healthcare and education. Alan shares insights on data management, privacy concerns, and the role of regulation in technology. The discussion extends to the personal experiences, touching on longevity, wellness, and the importance of sleep hygiene in the digital age. Alan also shares experiences from relocating to Portugal and Nokia’s investment in the country. Tune in to explore these topics and more in this insightful episode.
Alan Triggs is the Chief Digital Officer for Nokia globally, with responsibility for Nokia’s information technology (IT) and digitalisation initiatives. In this role, he is responsible for the global infrastructure for enterprise computing, networking, and end-user services, and enterprise applications covering R&D, services, supply, and financial & commercial systems. He is responsible for number of digital transformation initiatives including a company-wide cloud transformation, the modernisation of core application systems, and the corporate data strategy. Alan has held a number of leadership roles in IT; Telecom and has lived and worked in in seven countries across Africa, Europe and the US. He is currently based out of Portugal.
Other relevant references | Outras referências relevantes:
Blueprint (by Bryan Johnson)Contacts | Contactos:
CruzamentoPodcast.com [email protected] LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento Instagram: @cruzamentopodcast YouTube: Podcast CruzamentoEpisode edited by João Cunha Studios
-
Neste episódio do Podcast CRUZAMENTO, André Correia e Daniel Guedelha dialogam com Luís Oliveira, Senior Associate Director Research Programs na The Michael J. Fox Foundation, abordando a missão inspiradora da fundação, o impacto global das doenças neurodegenerativas em saúde e economia, e estratégias eficazes para mitigar riscos na Doença de Parkinson.
Luis Miguel Oliveira is a Senior Associate Director of Research Programs at The Michael J. Fox Foundation and the Founder of v-ATPase Alliance for rare diseases due to v-ATPase defects.
Luís is an expert in the field of Parkinson’s disease research and investment with more than 15 years of experience in the neurologic diseases space. Currently, he holds the position of Senior Associate Director of Research Programs at The Michael J. Fox Foundation, where he leads various efforts for therapeutic and biomarker development in priority genetic targets in Parkinson’s disease accounting for over $30 million in executed projects. Additionally, Luis Miguel Oliveira is a founder of the v-ATPase Alliance, an organization aimed at connecting families affected by rare diseases related to v-ATPase with the research and medical communities to further advance therapeutic development.
With a strong commitment to advance novel treatments from the bench to bedside, Luis Miguel Oliveira serves as a Review Editor for Frontiers in Neurology, Neuroscience and Psychiatry, and as an Investment Advisor for Portugal Ventures, where he leverages his expertise to guide investment decisions in promising ventures.
Recently, Luis Miguel Oliveira had an integral contribution to a landmark study that validated the first biomarker for Parkinson’s disease diagnosis. This significant achievement was reported in Lancet Neurology with broader international media coverage and is changing the Parkinson’s research and drug development fields by enabling an objective characterization of the disease based on its biological features.
Luis Miguel Oliveira’s educational background includes a degree in Biochemistry from the Faculty of Sciences of Lisbon University. He further pursued his academic journey with a PhD in Molecular Biophysics from the same institution. During his postdoctoral research experience, he conducted his studies at renowned institutions such as the Max Planck Institute for Biophysical Chemistry in Germany and Columbia University in New York.
Other relevant references | Outras referências relevantes:
v-ATPase Alliance (website) The Michael J. Fox Foundation (website)Contacts | Contactos:
CruzamentoPodcast.com [email protected] LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento Instagram: @cruzamentopodcast YouTube: Podcast Cruzamento -
In today’s CRUZAMENTO Podcast, André Correia e Daniel Guedelha talked with Stefan Buttigieg, about the impact of AI on healthcare. Highlights include AI’s potential in public health, data sharing challenges in Europe, AI projects in Malta, and the importance of equity and ethical data handling in healthcare.
Dr. Stefan Buttigieg is a Specialist in Public Health Medicine working in the Ministry for Health in Malta !🇲🇹 He is a Keynote Speaker with 50+ public speaking engagements track record and an avid content creator!📱🎙️. He is the manager of the National Contact Point of eHealth and lectures at the University of Malta on the topics of Digital Health, Social Media in Healthcare and Digital Therapeutics. He is the Vice-President of the EUPHA Section on Digital Health and is a WFPHA Governing Council Member. Dr Buttigieg is on a mission to enable equitable Digital Health and Health Data for All ensuring that no one is left behind
Other relevant references | Outras referências relevantes:
Stefan Buttigieg (Website) Yuval Noah Harari argues that AI has hacked the operating system of human civilisation Yuval Noah Harari at the Frontiers Forum - AI and the future of humanityContacts | Contactos:
CruzamentoPodcast.com [email protected] LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento Instagram: @cruzamentopodcast YouTube: Podcast Cruzamento -
In today’s CRUZAMENTO Podcast, André Correia and Daniel Guedelha talked with Ana França and António Gonçalves. They delve into Health, Technology, and Sustainability, with a focus on transplantation, common transplant types and their impact, insights from companies expanding globally, and future trends in transplantation technology. The discussion showcases TransplantHUB’s role in harnessing these advancements for patient benefit.
Meet Ana França, a highly skilled and dedicated organ donation and transplantation management expert. With over a decade of experience, Ana has been instrumental in transforming Portugal’s organ donation and transplantation system, improving patient outcomes, and increasing access to life-saving procedures for those in need. Her global initiatives in developing digital transplantation registries have revolutionized how organ donation and transplantation procedures are managed worldwide, earning her recognition as a leader in her field. Ana’s expertise in organ donation and transplantation and her passion for improving patient outcomes make her an invaluable asset to managing organ donation and transplantation.
With over 25 years of experience in IT Services, António Gonçalves brings together a vast experience in business analysis with a comprehensive technical area know-how in diverse industries, including Healthcare, Insurance, Local Government, Industry, and Logistics. This experience, and above all, the unquestionable ability to apply it in various sectors, allowed him not only to create reasonable conceptual solutions but, above all, practical solutions amenable to a linear technical implementation. His adaptability to a diverse audience, both functional and technical, has allowed him to design innovative products and, more importantly, create practical, innovative solutions with a linear technical implementation.
Other relevant references | Outras referências relevantes:
Transplant Hub (website)Contacts | Contactos:
CruzamentoPodcast.com [email protected] LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento Instagram: @cruzamentopodcast YouTube: Podcast Cruzamento -
Neste episódio do Podcast CRUZAMENTO, André Correia e Daniel Guedelha conversam com Patrícia Calado sobre estratégias de inovação e pesquisa na saúde, bem como a necessidade de avaliar adequadamente os investimentos públicos nesta área. A interdisciplinaridade na pesquisa médica é também destacada como crucial para solucionar problemas complexos de saúde.
Patrícia Calado is a results-driven professional dedicated to accelerating positive impact through the uptake of innovation into healthcare. Her career was built on collaborative work with healthcare institutions, industry, and research organizations all over the country. Currently she’s a member of the Board at NOVA Medical School (NMS), as Vice-Dean for Research, and she’s responsible for developing and implementing the faculty’s research and innovation strategy, in close articulation to the Dean.
Previously she worked for different innovation and funding agencies in Portugal as the National Contact Point and Delegate for Health in the EU Research and Innovation Programme (2015–2022). Between 2020 and 2022 she was a member of the Board at the Agency for Clinical Research and Biomedical Innovation (AICIB), were she led the international strategy of the Agency and set up the team of National Contact Points and Delegates for Health.
She has 25+ years of experience in the fields of Health and Life Sciences with experience in the coordination of multi-disciplinary teams in the context of academia, SME, and governmental agencies.
She’s driven by inspiring and motivating people to achieve a shared vision and goals. During her career she implemented processes of transformational leadership by encouraging innovation and empowering her teams to take risks and learn from mistakes, while creating a culture of trust, openness, and learning in the organization.
She has a PhD in Biomedical Sciences from the Faculty of Medicine of the University of Lisbon and a degree in Biology from the Faculty of Sciences and Technology of the University of Coimbra.
Other relevant references | Outras referências relevantes:
NOVA Medical School (NMS) (website) Agency for Clinical Research and Biomedical Innovation (AICIB) (website)Contacts | Contactos:
CruzamentoPodcast.com [email protected] LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento Instagram: @cruzamentopodcast YouTube: Podcast Cruzamento -
In today’s CRUZAMENTO Podcast, André Correia e Daniel Guedelha talked with Ron DePinho who delves into his contributions to cancer research and innovation, emphasizing the transformative potential of biotechnology in this critical field. His work is dedicated to advancing our understanding of cancer biology, enabling the development of more precise diagnostic tools and targeted therapies. Through his efforts, he aims to revolutionize the way we approach cancer treatment, with the ultimate goal of improving patient outcomes and quality of life. Additionally, Ron de Pinho actively engages in educating influential figures such as the President of the United States and the Pope, advocating for policies that support the advancement of biotechnology in healthcare and sustainability. His dedication to both research and advocacy solidifies his position as a leading figure in the biotech industry.
Ronald A. DePinho, M.D. is currently past president and distinguished university professor of The University of Texas MD Anderson Cancer Center. His research has focused on the fundamental mechanisms driving cancer and aging and the clinical application of such knowledge to prevent and treat disease.
Dr. DePinho studied biology at Fordham University, where he graduated class salutatorian, and received his M.D. degree with distinction in microbiology and immunology from the Albert Einstein College of Medicine. He performed his residency and postdoctoral training at Columbia-Presbyterian Medical Center.
Dr. DePinho’s independent career began at Einstein as the Feinberg Senior Faculty Scholar in Cancer Research and an ACS Research Professor. He then joined the Dana-Farber Cancer Institute and Harvard Medical School where he was the founding Director of the Belfer Institute for Applied Cancer Science and a Professor of Medicine and Genetics at Harvard. As president of MD Anderson, Dr. DePinho conceived and launched the Moon Shots Program, a goal-oriented comprehensive effort designed to accelerate declines in cancer incidence and mortality. This initiative has yielded practice-changing advances in cancer and inspired the national cancer moonshot under President Biden. He also elevated MD Anderson’s research and graduate programs, recruited many world class faculty including National Academy Members and its first Nobel Prize. To improve cancer care beyond MD Anderson, he launched and assembled a network of cancer institutions in 24 countries, reaching one-third of the human population.
As a researcher, he has published over 400 articles, books and chapters that have advanced our understanding of cancer, aging and degenerative disorders which have led to clinical advances including new cancer drugs and diagnostics. His most notable discoveries include elucidation of the core molecular pathway for aging, determination of the basis for the intimate link between advancing age and increased epithelial cancer incidence, establishment of the central role of telomeres in cancer genome instability, discovery of Sin3 and linkage of sequence specific transcription factors and chromatin regulators, demonstration that aging itself can be reversed which led to new therapeutic strategies for aging and age-related diseases including Alzheimer’s Disease. To translate these basic discoveries, he founded 9 private and publicly traded biotechnology companies and served as an advisor or director for biotech and large biopharma companies focused on oncology. His public service includes advisory and directorship roles for AACR and the NIH, as well as the Vatican and several countries. He is chairman and co-founder a non-profit, OPA Health (previously, Unite to Prevent Cancer) whose mission is disease prevention in underserved communities. As an advocate, he was a key instigator in the bipartisan bill raising the age of tobacco purchase to 21 (T21) and the bipartisan Cures Act. He is Vice Chair of the BOD for Act For NIH, a non-profit advocacy organization to garner bipartisan support for the NIH resulting in an additional $14.9B to the base budget and restoring the NIH budget following years of inflationary decline.
For his fundamental contributions to cancer and aging and to healthcare, he has been recognized with numerous honors and awards. He was named one of the 100 most influential healthcare leaders, according to Modern Healthcare. His honors include the Melini Award for Biomedical Excellence, the American Society for Clinical Investigation Award, the Biomedicum Helsinki Medal, Albert Szent-Györgyi Prize, AACR Clowes Award, American-Italian Foundation Prize, among others. He is a member of the National Academy of Medicine and the National Academy of Science, and a fellow of the American Academy of Arts and Sciences, the American Association of the Advancement of Science and the American Association of Cancer Research. He received Fordham University’s McMahon Memorial Award for Distinguished Public Service, honorary degrees from Harvard University and Hofstra University, and the Ellis Island Medal of Honor. For his work to improve the health of Portugal’s people, Dr. DePinho was recognized by its president with the highest commendation, the Order of Saint James of the Sword.
Other relevant references | Outras referências relevantes:
Ron DePinho (website) Lynda Chin (website) MD Anderson Cancer Center (website)Contacts | Contactos:
CruzamentoPodcast.com [email protected] LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento Instagram: @cruzamentopodcast YouTube: Podcast Cruzamento -
In today’s CRUZAMENTO Podcast, André Correia e Daniel Guedelha talked with Katrien Buys about her experiences in the AXA and Ageas merger, highlighting the challenges faced and the strategies that led to success. She also discussed Impact Investing, a concept that stirs controversy among traditional investors, drawing from her role at the Ageas Foundation. Katrien’s inspiring take on Innovation and the Role of Failure underscores how failures can drive progress, backed by compelling examples. This interview offers a profound exploration of these crucial topics that resonate universally.
Katrien Buys was born and raised in Belgium, and a mathematician by education at the Catholic University of Leuven (KU Leuven Belgium). This degree led her to start in the insurance industry where she worked in the Belgian entity of the group during several years. Triggered by a need of exploring the business world beyond its boundaries, a guiding principle that she keeps valid until today, she set off in 2012 to join the Italian operations and have her first international working experience. After a return to Belgium for 2 years, leading a strategic transformation program, she took the bigger opportunity of travelling and moving with her family to Portugal. Katrien bridges the gap between her work at Ageas Portugal and impact organizations, creating new business opportunities for positive societal impact. She likes to be innovative and to always find ways to cooperate in different areas, creating value both for these organizations and for Ageas Portugal. More importantly, she asks questions regularly, most often “why?” which is the most powerful question to keep you on track and ensure you don’t take anything for granted. Because she works in strategy, innovation and sustainability, she sees her role as bringing people together, having good conversations and co-creating a world of hope for as many people as possible. In the spirit of Ageas Portugal’s mission to deliver emotional and meaningful experiences in people’s lives, there is the vision that, with radical collaboration, we can be a welcome presence in every Portuguese household. Katrien is the winner of the 2021 MAZE Runner Award.
Other relevant references | Outras referências relevantes:
Impact Investing Explained: Definition, Types, and Examples Podcast Cruzamento #65: Gabrielle Fitzgerald: Philanthropy, a platform for social change Podcast Cruzamento #71: Carlos Oliveira: Qual o impacto das Fundações no ecossistema?Contacts | Contactos:
CruzamentoPodcast.com [email protected] LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento Instagram: @cruzamentopodcast YouTube: Podcast Cruzamento - Laat meer zien
![91: Cristina Campos: Liderança com Propósito [PT]](https://is1-ssl.mzstatic.com/image/thumb/Podcasts126/v4/91/38/d9/9138d920-1a8b-c96e-4f46-8e65dbadd6ed/mza_9737997980080240958.jpg/80x80bb.jpg)